pharma

YOU MIGHT BE INTERESTED IN

Smoking Cessation Report, 2009-2024
Smoking is the leading cause of preventable death in the world. The effects of smoking represent a global pandemic of enormous proportions. Currently-marketed smoking cessation aids typically lack high levels of efficacy in practice and are associated with marked side-effects. There are clear market opportunities for novel, more-efficacious and safer smoking cessation agents, in both prescription and OTC forms.
...more details
World Smoking-Cessation Drug Market 2010-2025
Smoking is a leading cause of preventable death worldwide. In 2009, total sales of smoking-cessation products surpassed $1.6bn (Rx products). The effects of smoking constitute a major burden on public healthcare systems, as well as lowering quality of life for many people. Currently-marketed smoking-cessation products arguably lack the desired levels of efficacy in practice, with the reputation of some suffering through noted side-effects. As a result, there are significant commercial opportunities for more-efficacious and better-tolerated smoking-cessation agents, especially in prescription form.
...more details
The Global Pain Market, 2008-2023
The global pain market generated total sales of $34bn in 2007 – but what will the figures be in the next 5 and 10 years? This report tells you.
...more details
Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024
Obesity has been described as a 'public health time-bomb'. In 2005, the World Health Organization estimated that approximately 400 million individuals are obese. Prevalence of obesity is rising worryingly in many countries, despite campaigns emphasising the link between being overweight and contracting diabetes. This new report - Anti-Obesity Treatments 2009-2024 - explains those trends in commercial terms.
...more details
The Global Vaccines Market 2008-2023
The key growth driver for vaccines is their cost-effectiveness in combating disease. This situation will encourage greater use of vaccines by governments and private healthcare providers. New disease targets that could be mitigated through vaccination, including high profile (and potentially profitable) targets such as cancer.
...more details
The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023
Visiongain have the pleasure of announcing the latest edition of their industry leading report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the world OTC market at present and predicts its sales revenues and trends from 2008-2023, including drivers and restraints on the market.
...more details

REPORT

...see all

The Global Anti-Addiction Market, 2008-2023

Download report Download sample

Publication date: 05/11/2008
Number of Pages: 138

Report Details
Table of Contents
Companies Listed

Report Details

The global addiction market is significantly undervalued. The world’s population has a large unmet need for addiction therapy drugs. Are you ready for the opportunities this presents? The brand new report, The Global Anti-Addiction Market, 2008-2023, provides an in-depth analysis of the current state of the market for addiction therapy drugs, from the present looking forward. It covers the major therapy areas of smoking cessation, obesity, drug addiction and alcohol dependency. In addition, this study forecasts how your market will grow and develop, both quantitatively and qualitatively, during the period 2008-2023.

The Global Anti-Addiction Market, 2008-2023, uses a variety of primary and secondary research methods, including:
• Exclusive visiongain interviews with key opinion leaders in the addiction industry
• Examination of a wealth of secondary sources, including company reports, filings, analyst presentations and press releases
• Use of in-house and commercial sales databases.

Addiction rates are increasing, yet there is a relative lack of widely-efficacious drugs. Also, relatively few patients are treated and patient compliance is low for those who are treated at present. Nevertheless, the growth potential market of this market is significant, both in developed and developing countries. In addition, awareness of the human and healthcare costs associated with addiction is increasing amongst patients, healthcare practitioners and legislators. There is a sense of urgency to combat tobacco addiction, alcoholism and obesity in particular. Consequently, there are marked opportunities for companies marketing and developing anti-addiction drugs. But by how much will the market grow and which therapy areas will be the fastest growing? This report answers those questions and more besides.

Visiongain has applied detailed financial forecasting and analysis of market/industry drivers and restraints, including SWOT analysis. The resulting comprehensive market-based report reveals how leading addiction brands, therapy areas and markets will fare during the period 2008 to 2023. Key features of the addiction drugs of the future and the hurdles they will have to overcome for commercial success are discussed.

Other highlights of The Global Anti-Addiction Market, 2008-2023 report include:
• Expert opinion from representatives in the anti-addiction drug industry
• Sales forecasts for the global addiction market and for individual obesity, smoking cessation, drug addiction and alcohol addiction markets, including leading brands, manufacturers and country markets
• Examination of strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the anti-addiction drugs market
• In-depth analysis of the anti-addiction pipeline
• Geographical breakdown of the anti-addiction drugs market
• Analysis of the addiction markets in the US, France and the UK.

Why you should buy this report:
• To receive a comprehensive analysis of the prospects for anti-addiction drugs, including key metrics and predicted revenues, by type of addiction and brand
• To receive forecasts of addiction drug sales, from 2008-2023, in leading country markets, including China and Mexico
• To read the views of experts in the addiction industry, regarding current and future trends, opportunities and sales drivers; the report includes full transcripts of interviews
• The report is packed with graphs, charts, figure and tables of analysis and sales forecasts
• To determine the forces that influence the market for anti-addiction drugs: drivers, restraints, opportunities and competitive factors
• To find out where the addiction market is heading - both technologically and commercially from 2008 onwards.

The information contained in this report is not available in any other source and is essential reading for you and your colleagues. By ordering and reading this report you can gain market advantage on your competitors today. When aligned with your in-house findings we are confident you will continue to succeed over the next 15 years.

1 Executive Summary

2 Introduction: Worldwide Prevalence and Treatment of Addiction
2.1 The Physiology and Psychology of Addiction
2.1.1 Definition of Addiction
2.1.2 Addiction is Caused by Physical Dependence
2.1.3 Psychological Dependence
2.2 Prevalence of Addiction
2.3 Addiction Therapy
2.3.1 Behavioural Therapy
2.3.2 Addiction Treatment with Drugs
2.3.3 Off-Label Drug Prescribing for Addiction Therapy
2.4 Smoking Cessation Products
2.4.1 Nicotine Replacement Therapy (NRT)
2.4.2 Nicotine Replacement Therapy Products (Johnson & Johnson)
2.4.3 Nicotine Replacement Therapy Products (GSK)
2.4.4 Nicotine Replacement Therapy Products (Novartis)
2.4.5 Chantix/Champix (Pfizer)
2.4.6 Zyban (GSK/Biovail)
2.5 Obesity Drugs
2.5.1 Xenical (Roche)
2.5.2 Reductil/Meridia (Abbott Laboratories)
2.5.3 Alli (GSK)
2.5.4 Acomplia (Sanofi-Aventis)
2.5.5 Other Obesity Drugs
2.6 Drugs Used In Opioid Dependence
2.6.1 Suboxone/Subutex (Reckitt Benckiser/ Schering-Plough)
2.6.2 Methadone
2.6.3 Naltrexone
2.6.4 Other Drugs Used in Opioid Addiction Treatment
2.7 Alcohol Dependency Drugs
2.7.1 Campral/Aotal (Merck KGaA/Forest)
2.7.2 Antabuse (Barr)
2.7.3 Naltrexone
2.7.4 Vivitrol (Alkermes/Cephalon/Johnson & Johnson)
2.7.5 Revia (Barr/Bristol-Myers Squibb)

3 The Global Addiction Market
3.1 The Addiction Market in 2007
3.1.1 Leading Addiction Therapy Areas, 2007
3.1.2 Leading Addiction Brands, 2007
3.1.3 Leading Manufacturers of Addiction Drugs, 2007
3.2 Global Addiction Market Forecasts, 2008-2023
3.2.1 Addiction Market Forecast, 2008-2023
3.2.2 Addiction Therapy Area Sales Forecast, 2008-2023

4 The Global Smoking Cessation Market
4.1 The Smoking Cessation Market in 2007
4.1.1 Leading Smoking Cessation Product Types, 2007
4.1.2 Leading Manufacturers of Smoking Cessation Products, 2007
4.2 Smoking Cessation Market Forecasts, 2008-2023
4.2.1 Global Smoking Cessation Market Forecast, 2008-2023
4.2.2 Smoking Cessation Product Type Sales Forecast, 2008-2023
4.2.3 Chantix/Champix Sales Forecast, 2008-2023

5 The Global Obesity Market
5.1 The Obesity Market in 2007
5.1.1 Leading Obesity Brands, 2007
5.1.2 Leading Manufacturers of Obesity Drugs, 2007
5.2 Obesity Market Forecasts, 2008-2023
5.2.1 Global Obesity Market Forecast, 2008-2023
5.2.2 Xenical Sales Forecast, 2008-2023
5.2.3 Reductil/Meridia Sales Forecast 2008-2023
5.2.4 Alli Sales Forecast, 2008-2023
5.2.5 Acomplia Sales Forecast, 2008-2023

6 The Global Drug Addiction Market
6.1 The Drug Addiction Market in 2007
6.1.1 Leading Drug Addiction Product Types, 2007
6.1.2 Leading Manufacturers of Drug Addiction Products, 2007
6.2 Drug Addiction Market Forecasts, 2008-2023
6.2.1 Global Drug Addiction Market Forecast, 2008-2023
6.2.2 Drug Addiction Product Type Sales Forecast, 2008-2023
6.2.3 Suboxone/Subutex Sales Forecast, 2008-2023

7 The Global Alcohol Dependency Market
7.1 The Alcohol Dependency Market in 2007
7.1.1 Leading Alcohol Dependency Drug Types, 2007
7.1.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007
7.2 Alcohol Dependency Market Forecasts, 2008-2023
7.2.1 Global Alcohol Dependency Market Forecast, 2008-2023
7.2.2 Alcohol Dependency Drug Type Sales Forecast, 2008-2023
7.2.3 Campral/Aotal Forecast, 2008-2023
7.2.4 Vivitrol Sales Forecast, 2008-2023

8 Leading Addiction Country Markets
8.1 Top Twelve Addiction Country Markets, 2007
8.2 Addiction Market Country Forecasts, 2008-2023
8.3 The US Addiction Market
8.3.1 Prevalence of Addiction in the US
8.3.2 Smoking Cessation Dominated the US Addiction Market in 2007
8.3.3 Forecast for the US Addiction Market, 2008-2023
8.4 The UK Addiction Market
8.4.1 Prevalence of Addiction in the UK
8.4.2 There is Greater Reimbursement of Addiction Drugs in the UK Market
8.4.3 Forecast for the UK Addiction Market, 2008-2023
8.5 The French Addiction Market
8.5.1 Prevalence of Addiction in France
8.5.2 France has High Revenues in the Drug and Alcohol Addiction Markets
8.5.3 Forecast for the French Addiction Market, 2008-2023

9 SWOT Analysis of the Addiction Market
9.1 Analysis of the Market
9.2 Strengths of the Addiction Industry
9.2.1 Development of Addiction Vaccines and Novel Drug Formulations
9.2.2 Expansion into New Therapeutic Areas
9.3 Weaknesses of the Addiction Therapy Industry
9.3.1 Currently Marketed Addiction Therapies Lack Efficacy
9.3.2 Poor Patient Compliance
9.4 Opportunities in the Addiction Market
9.4.1 Addiction is Prevalent Worldwide and Increasing
9.4.2 Prevalence of Tobacco Use Worldwide and in Major Country Markets
9.4.3 Prevalence of Obesity Worldwide and in Major Country Markets
9.4.4 Prevalence of Drug Use Worldwide and in Major Country Markets
9.4.5 Alcohol Consumption and Dependence Worldwide and in Major
Country Markets
9.4.6 There is Considerable Under-Treatment of Patients
9.4.7 The Cost of Addiction is High
9.4.8 Awareness of the Costs of Addiction is Increasing
9.4.9 Smoking Legislation is Spreading
9.5 Threats to the Addiction Market
9.5.1 Reimbursement is the Key to Success in the Addiction Market
9.5.2 Concern over Side-Effects of Addiction Drugs
9.5.3 Behavioural Therapy is Often Preferred to Treatment with Drugs
9.5.4 Social Stigma and Lack of Education and Resources

10 The Addiction Therapy Pipeline
10.1 Some Areas of the Addiction Pipeline are Stronger than Others
10.2 The Smoking Cessation Product Pipeline
10.2.1 Addiction Vaccines Will Target Nicotine Dependence
10.2.2 Surinabant (Sanofi-Aventis)
10.2.3 EVT 302 (Evotec)
10.2.4 NicVAX (Nabi Biopharmaceuticals)
10.2.5 NIC002 (Cytos Biotechnology/Novartis)
10.2.6 TA-NIC (Celtic Pharma)
10.2.7 Niccine (Independent Pharmaceutica)
10.3 The Obesity Drug Pipeline
10.3.1 The Obesity Pipeline has had a High Failure Rate
10.3.2 Contrave (Orexigen)
10.3.3 CP-945598/Otenabant (Pfizer)
10.3.4 Lorcaserin (Arena)
10.3.5 Qnexa (Vivant)
10.3.6 ATL-962/Cetilistat (Alizyme/Takeda)
10.3.7 Pramlintide/Metreleptin (Amylin)
10.3.8 Histalean (OBEcure)
10.3.9 Empatic (Orexigen)
10.3.10 Liraglutide (Novo Nordisk)
10.4 The Drug Addiction Therapy Pipeline
10.4.1 Cocaine Treatment is the Most Promising Drug Addiction Pipeline Area
10.4.2 Vivitrol (Alkermes)
10.4.3 Probuphine (Titan)
10.4.4 TA-CD (Celtic Pharma)
10.4.5 SYN-117 (Synosia Therapeutics/Roche)
10.4.6 Lobeline (Yaupon Therapeutics)
10.4.7 Naltrexone Implant (Indevus)
10.4.8 Tetrodin (WEX Pharmaceuticals)
10.4.9 XY2401 (Xytis/National Institute on Drug Abuse/Rottapharm)
10.5 The Alcohol Dependency Therapy Pipeline
10.5.1 The Alcohol Dependency Pipeline Has Plenty of Room for Novel Products
10.5.2 Nalmefene (Biotie Therapies /Lundbeck/Somaxon): A New Drug for Dependency Disorders
10.5.3 Naltrexone Depot (Elbion NV)
10.5.4 ALKS 29 (Alkermes)
10.6 The Pipeline for Other Addiction Therapies

11 Expert Opinion from Key Opinion-Leaders in the Addiction Industry
11.1 Dr Raafat Fahim, President and Chief Executive Officer, Nabi Biopharmaceuticals
11.1.1 Vaccines in the Pipeline for Nicotine Addiction
11.1.2 NicVAX
11.1.3 Other Nicotine Vaccines
11.2 Industry Representative from the Addiction Therapy Sector
11.2.1 Type of Addictions with Greatest Market Growth Potential
11.2.2 Key Unmet Needs For Alcohol Dependent Patients
11.2.3 Key Advantages of Nalmefene
11.2.4 The Future of the Alcohol Dependency Market

12 Conclusions
12.1 The Addiction Market in 2007
12.2 Opportunity for Growth in the Addiction Market
12.3 Visiongain's Forecast for the Addiction Market, 2008-2023

List of Tables
Table 2.1 Global Prevalence of Addiction and Drug Use
Table 2.2 Key Drugs Prescribed Off-Label for Addiction Therapy
Table 2.3 Major Johnson & Johnson Nicotine Replacement Therapy Brands
Table 2.4 Major GSK Nicotine Replacement Therapy Brands
Table 2.5 Major Novartis Nicotine Replacement Therapy Brands
Table 3.1 Leading Addiction Therapy Areas, 2007
Table 3.2 Leading Addiction Brands, 2007
Table 3.3 Leading Manufacturers of Addiction Drugs, 2007
Table 3.4 Global Addiction Market Forecast, 2008-2013
Table 3.5 Global Addiction Market Forecast, 2014-2023
Table 3.6 Addiction Therapy Area Sales Forecast, 2008-2013
Table 3.7 Addiction Therapy Area Sales Forecast, 2014-2023
Table 4.1 Leading Smoking Cessation Product Types, 2007
Table 4.2 Leading Manufacturers of Smoking Cessation Products, 2007
Table 4.3 Global Smoking Cessation Market Forecast, 2008-2013
Table 4.4 Global Smoking Cessation Market Forecast, 2014-2023
Table 4.5 Smoking Cessation Product Type Sales Forecast, 2008-2013
Table 4.6 Smoking Cessation Product Type Sales Forecast, 2014-2023
Table 5.1 Leading Obesity Brands, 2007
Table 5.2 Leading Manufacturers of Obesity Drugs, 2007
Table 5.3 Global Obesity Market Forecast, 2008-2013
Table 5.4 Global Obesity Market Forecast, 2014-2023
Table 5.5 Obesity Brands Sales Forecasts, 2008-2013
Table 5.6 Obesity Brands Sales Forecasts, 2014-2023
Table 6.1 Leading Drug Addiction Product Types, 2007
Table 6.2 Leading Manufacturers of Drug Addiction Products, 2007
Table 6.3 Global Drug Addiction Market Forecast, 2008-2013
Table 6.4 Global Drug Addiction Market Forecast, 2014-2023
Table 6.5 Drug Addiction Product Type Sales Forecast, 2008-2013
Table 6.6 Drug Addiction Product Type Sales Forecast, 2014-2023
Table 6.7 Suboxone/Subutex Sales Forecast, 2008-2013
Table 6.8 Suboxone/Subutex Sales Forecast, 2014-2023
Table 7.1 Leading Alcohol Dependency Drug Types, 2007
Table 7.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007
Table 7.3 Global Alcohol Dependency Market Forecast, 2008-2013
Table 7.4 Global Alcohol Dependency Market Forecast, 2014-2023
Table 7.5 Alcohol Dependency Drug Type Sales Forecast, 2008-2013
Table 7.6 Alcohol Dependency Drug Type Sales Forecast, 2014-2023
Table 7.7 Campral/Aotal and Vivitrol Sales Forecast, 2008-2013
Table 7.8 Campral/Aotal and Vivitrol Sales Forecast, 2014-2023
Table 8.1 Top Twelve Addiction Country Markets, 2007
Table 8.2 Addiction Market Country Forecasts, 2008-2013
Table 8.3 Addiction Market Country Forecasts, 2014-2023
Table 8.4 Prevalence of Addiction and Drug Use in the US
Table 8.5 The US Addiction Market, 2007
Table 8.6 Prevalence of Addiction and Drug Use in the UK
Table 8.7 The UK Addiction Market, 2007
Table 8.8 Prevalence of Addiction and Drug Use in France
Table 8.9 The French Addiction Market, 2007
Table 9.1 SWOT Chart for Addiction Market
Table 9.2 Prevalence of Tobacco Use Worldwide and in Major Country Markets
Table 9.3 Prevalence of Obesity Worldwide and in Major Country Markets
Table 9.4 Worldwide Drug Use, 2006/07
Table 9.5 Prevalence of Opioid Drug Use Worldwide and in Major Country Markets
Table 9.6 Prevalence of Cocaine Use Worldwide and in Major Country
Table 9.7 Alcohol Consumption & Dependence Worldwide & in Major Country Markets
Table 10.1 Key Smoking Cessation Pipeline Products
Table 10.2 Key Obesity Pipeline Drugs
Table 10.3 Key Drug Addiction Pipeline Therapies
Table 10.4 Key Alcohol Dependency Pipeline Drugs

List of Figures
Figure 3.1 Leading Addiction Therapy Areas, 2007
Figure 3.2 Leading Addiction Brands, 2007
Figure 3.3 Leading Manufacturers of Addiction Drugs, 2007
Figure 3.4 Global Addiction Market Forecast, 2008-2023
Figure 3.5 Addiction Therapy Area Sales Forecast, 2008-2023
Figure 3.6 Addiction Therapy Area Sales Forecast and Market Share, 2008-2023
Figure 3.7 Addiction Therapy Area Market Share, 2013
Figure 3.8 Addiction Therapy Area Market Share, 2018
Figure 3.9 Addiction Therapy Area Market Share, 2023
Figure 4.1 Leading Smoking Cessation Product Types, 2007
Figure 4.2 Leading Manufacturers of Smoking Cessation Products, 2007
Figure 4.3 Global Smoking Cessation Market Forecast, 2008-2023
Figure 4.4 Smoking Cessation Product Type Sales Forecast, 2008-2023
Figure 4.5 Smoking Cessation Product Type Sales Forecast & Market Share, 2008-2023
Figure 4.6 Chantix/Champix Sales Forecast, 2008-2023
Figure 5.1 Leading Obesity Brands, 2007
Figure 5.2 Leading Manufacturers of Obesity Drugs, 2007
Figure 5.3 Global Obesity Market Forecast, 2008-2023
Figure 5.4 Xenical Sales Forecast, 2008-2023
Figure 5.5 Reductil/Meridia Sales Forecast, 2008-2023
Figure 5.6 Alli Sales Forecast, 2008-2023
Figure 5.7 Acomplia Sales Forecast, 2008-2023
Figure 6.1 Leading Drug Addiction Product Types, 2007
Figure 6.2 Leading Manufacturers of Drug Addiction Products, 2007
Figure 6.3 Global Drug Addiction Market Forecast, 2008-2023
Figure 6.4 Drug Addiction Product Type Sales Forecast, 2008-2023
Figure 6.5 Drug Addiction Product Type Sales Forecast and Market Share, 2008-2023
Figure 6.6 Suboxone/Subutex Sales Forecast, 2008-2023
Figure 7.1 Leading Alcohol Dependency Drug Types, 2007
Figure 7.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007
Figure 7.3 Global Alcohol Dependency Market Forecast, 2008-2023
Figure 7.4 Alcohol Dependency Drug Type Sales Forecast, 2008-2023
Figure 7.5 Alcohol Dependency Drug Type Sales Forecast and Market Share, 2008-2023
Figure 7.6 Campral/Aotal Sales Forecast, 2008-2023
Figure 7.7 Vivitrol Sales Forecast, 2008-2023
Figure 8.1 Leading Addiction Country Markets, 2007
Figure 8.2 Leading Addiction Country Markets, 2013
Figure 8.3 Leading Addiction Country Markets, 2018
Figure 8.4 Leading Addiction Country Markets, 2023
Figure 8.5 The US Addiction Market, 2007
Figure 8.6 US Addiction Market Sales Forecast, 2008-2023
Figure 8.7 The UK Addiction Market, 2007
Figure 8.8 UK Addiction Market Sales Forecast, 2008-2023
Figure 8.9 The French Addiction Market, 2007
Figure 8.10 French Addiction Market Sales Forecast, 2008-2023
Figure 9.1 Top-Ten Countries for Numbers of Tobacco Users
Figure 9.2 Prevalence of Obesity in Major Country Markets
Figure 9.3 Prevalence of Opioid Drug Use in Major Country Markets
Figure 9.4 Prevalence of Cocaine Use in Major Country Markets
Figure 9.5 Alcohol Consumption and Dependence in Major Country Markets

Companies Listed

Abbott Laboratories
Actavis
Alizyme
Alkermes
Amylin
Arena
AstraZeneca
Barr
Biotie Therapies (Finland)
Biovail
Bristol-Myers Squibb
Celtic Pharma
Cephalon
CV Therapeutics
Cytos Biotechnology
Drake University (US)
Eisai
Elbion NV
Eli Lilly
European Medicines Agency (EMEA)
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
Evotec
Food and Drug Administration (FDA)
Forest
GSK
Independent Pharmaceutica
Indevus
Johnson & Johnson
Karolinska Institutet (Sweden)
Lundbeck
Medley (Brazil)
Merck & Co.
Merck KGaA
Nabi Biopharmaceuticals
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute on Drug Abuse (NIDA, USA)
National Institutes of Health (NIH, USA)
Novartis
Novo Nordisk
OBEcure
Orexigen
Pfizer
Reckitt Benckiser
Roche
Rottapharm (Italy)
Sanofi-Aventis
Schering-Plough
Solvay
Somaxon
Synosia Therapeutics
Takeda
Titan
Vivant
WEX Pharmaceuticals
World Health Organization (WHO)
Xytis
Yaupon Therapeutics

YOU MIGHT BE INTERESTED IN

Smoking Cessation Report, 2009-2024

World Smoking-Cessation Drug Market 2010-2025

The Global Pain Market, 2008-2023

Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024

The Global Vaccines Market 2008-2023

The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023

REPORT

The Global Anti-Addiction Market, 2008-2023

Report Details

Table of Contents

Companies Listed